Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

Babies in Glasses; a Feasibility Study. (BiG)

28 de septiembre de 2022 actualizado por: Great Ormond Street Hospital for Children NHS Foundation Trust

Can Provision of Near Vision Glasses as an Early Intervention Improve Visual and Developmental Outcomes in Children With Perinatal Brain Insult? A Feasibility Study.

This is a feasibility study to begin investigating the possibility that early use of near vision glasses will improve vision in infants at risk of Cerebral Visual Impairment (CVI), leading to further improvement in other areas of development. This active intervention, starting at either 2 or 4 months of age (depending on randomisation), could be more effective than waiting until a problem is detected before giving glasses.

As this is a feasibility study, the investigators are looking at a small sample of babies (n=75) to see whether their parents/carers are willing to take part in a 3-arm study comparing two differently timed interventions to a control group, as well as looking at different aspects of the research plan in preparation for a larger final study.

Descripción general del estudio

Descripción detallada

The aim of this study is to assess the feasibility and the acceptability of randomisation and the intervention, namely near vision glasses, from parents of very young babies at risk of Cerebral Visual Impairment (CVI).

All infants are born with an immature visual system, and for vision to develop normally, a clear image needs to transmit to the visual centres of the brain.

Good vision plays an important role in facilitating normal development so if CVI goes unnoticed, it can have a damaging effect on the child's early development, and subsequent education and quality of life. Children use their sight to learn to walk, talk, think and communicate. For this reason, early intervention has the potential to have positive effects on children's vision and general development.

Previous studies have shown that up to 75% of school age children, who have CVI, have difficulty focussing their eyes on a near target, so near objects, such as their hands and parents' faces, will appear blurry. These studies also showed that wearing glasses for near focus improved vision but has not been assessed in babies.

This is a single-centre, parallel group, open-label feasibility trial to assess the feasibility of testing the effect near vision glasses (full cycloplegic refraction plus 3.00D add for near) could have on the visual and developmental outcome in babies at risk of brain injury.

Infants at risk of developing CVI include those who have had hypoxic ischaemic encephalopathy (HIE) and those born prematurely before 29 weeks gestation.

The paediatric research optometrist will enrol and assess all eligible babies of consenting families; first visit at 8 or 16 weeks corrected gestational age, depending on randomisation. Each infant will be followed up 3 months and 6-months (+/- 3 weeks) after the first visit.

There are three main areas of the assessment, which will be leading to potential primary outcome measures:

  1. Visual Responses (including visual acuity and refractive status)

    At each visit, vision will be evaluated using Atkinson's battery for Child Development for Examining Functional Vision (ABCDEFV) according to the child's age and their ability. This comprises age-appropriate core vision tests (such as visual acuity and fixing and following) as well as additional tests that assess visual perception and visuomotor behaviour. If visual acuity cannot be obtained using Keeler acuity cards, as per ABCDEFV, the children will receive a measure using a Near Detection Scale (NDS).

  2. General Development and Neurodevelopmental Delay

    Non-visual developmental assessments will include the Bayley Scales of Infant Development - 3rd edition (BSID-III) assessment as appropriate for age at routine neonatal clinical appointments at 3, 6,12 and 24 months (not the research clinics). A Prechtl video will also be performed at the 3-month appointment to assess the presence of fidgety movements. The presence of these movements at 3 months corrected gestational age has been strongly correlated with normal motor development.

  3. Functional broadband near infrared spectroscopy (fBNIRS)

    i. Identification of changed functional haemodynamic and metabolic response to visual stimulus in infants at risk of visual dysfunction.

    ii. Assessment of changes in functional response in relation to response to glasses

    Eligible children with consenting parents will be screened for high refractive error prior to randomisation by the research optometrist to avoid post-randomisation dropouts. Evidence of high refractive error (more than -6.00D spherical equivalent or +8.00D spherical equivalent) will result in a referral to ophthalmology and exclusion from the study due to the possibility of associated ocular pathology with high refractive error.

    All of the above assessments have been organised at University College London Hospitals (UCLH). If the infant is randomised to get glasses, they will be given a near vision spectacle prescription (full cycloplegic refraction plus 3.00D add for near) to take to Great Ormond Street Hospital Eye Department dispensing optician to get the special glasses ordered.

    Expert ethical advice has been sought through the NIHR's Research Design Service to check on the dimension of potential harm (with a positive review). Each case will be monitored by the independent data monitoring and ethics committee (IDMEC) using follow up data who will report to the trial steering committee (TSC). The IDMEC, Trial Steering Committee (TSC) and Trial Management Group (TMG) will oversee the conduct of this trial.

Tipo de estudio

Intervencionista

Inscripción (Actual)

55

Fase

  • No aplica

Contactos y Ubicaciones

Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.

Ubicaciones de estudio

      • London, Reino Unido, WC1E 6DB
        • University College London Hospital

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

No mayor que 1 mes (Niño)

Acepta Voluntarios Saludables

No

Géneros elegibles para el estudio

Todos

Descripción

Inclusion criteria:

  1. All term infants undergoing therapeutic hypothermia for hypoxic ischaemic encephalopathy (HIE).
  2. All preterm infants born at <29 weeks gestational age.

Specifically, all children fulfilling these criteria will be eligible. Evidence of hypo-accommodation is not required.

Exclusion criteria:

  1. Infants that are still an inpatient at 8 weeks corrected gestational age.
  2. Ocular exclusion criteria: children with unrelated congenital or developmental ocular abnormality such as cataract requiring surgery, genetic retinal disease, coloboma. Retinopathy of prematurity will not be an exclusion criterion.
  3. Infants with high refractive error (more than -6.00D spherical equivalent or +8.00D spherical equivalent).

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

  • Propósito principal: Otro
  • Asignación: Aleatorizado
  • Modelo Intervencionista: Asignación paralela
  • Enmascaramiento: Ninguno (etiqueta abierta)

Armas e Intervenciones

Grupo de participantes/brazo
Intervención / Tratamiento
Sin intervención: A (control)
First visit assessments at 8 weeks corrected gestational age. No glasses prescribed.
Experimental: B1 (intervention)
First visit assessments at 8 weeks corrected gestational age. Full time spectacle wear prescribed.
Near vision spectacles prescribed for full time wear (Add+3.00DS to the full cycloplegic refraction). These glasses will be changed to reflect changes in refractive error or frame fit as appropriate at follow up.
Experimental: B2 (intervention)
First visit assessments at 16 weeks corrected gestational age. Full time spectacle wear prescribed.
Near vision spectacles prescribed for full time wear (Add+3.00DS to the full cycloplegic refraction). These glasses will be changed to reflect changes in refractive error or frame fit as appropriate at follow up.

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Medida Descripción
Periodo de tiempo
The acceptance of randomisation
Periodo de tiempo: 10 months
This will be measured as the proportion of patients/parents who accept the offer of randomisation.
10 months

Medidas de resultado secundarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Success rate in dispensing glasses to children in groups B1 and B2.
Periodo de tiempo: 6 months
The percentage of infants dispensed vs. the total number of infants randomised to the intervention arms will be recorded at the end of the study.
6 months
Success rate of compliance with glasses for infants in groups B1 and B2.
Periodo de tiempo: 6 months
The proportion of infants (%) who are still wearing their glasses at the 3 and 6 month follow-up appointments.
6 months
Visual Acuity
Periodo de tiempo: 6 months
The distribution of visual acuity at the 3 and 6-month follow ups compared with visual acuity at the first visit in all 3 arms.
6 months
Retention rate
Periodo de tiempo: 15 months
This will be measured by the median number of infants reported per month.
15 months
Refractive outcomes
Periodo de tiempo: 6 months
The distribution of refractive outcomes (measured in dioptres) at 3 and 6-month follow ups as compared to the first visit in all 3 groups.
6 months
Evidence of impaired emmetropisation following administration of FMT
Periodo de tiempo: 6 months
This will be measured by combining refractive error and visual acuity measures. The trial will not be feasible if there is a 2SD difference without compensatory benefit eg 2 lines improvement in visual acuity.
6 months
Determination of appropriate resource-use data collection methods
Periodo de tiempo: 15 months
A targeted paediatric client service receipt inventory (CSRI) form has been designed specifically for this population and will be used for the duration of the feasibility study.
15 months
Accommodative outcomes
Periodo de tiempo: 6 months
The distribution of accommodative outcomes (measured in dioptres) at 3 and 6-month follow ups as compared to the first visit in all 3 groups.
6 months
Completion of compliance questionnaires
Periodo de tiempo: 6 months
Proportion of families completing phone questionnaire on spectacle compliance as a percentage of those in the intervention groups (B1 & B2).
6 months
Significant mechanical trauma
Periodo de tiempo: 6 months
Significant mechanical trauma will be measured as the percentage of infants who have had an adverse event (from mechanical trauma) vs. the total number of infants prescribed glasses in groups B1 and B2. The study will not be feasible if this is more than 30% of infants in the intervention arms.
6 months
Consent rate
Periodo de tiempo: 10 months
This will be measured as the number of infants recruited vs. number of infants, who fulfil the inclusion/exclusion criteria, approached.
10 months

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Publicaciones y enlaces útiles

La persona responsable de ingresar información sobre el estudio proporciona voluntariamente estas publicaciones. Estos pueden ser sobre cualquier cosa relacionada con el estudio.

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio (Actual)

9 de septiembre de 2021

Finalización primaria (Anticipado)

9 de junio de 2023

Finalización del estudio (Anticipado)

31 de diciembre de 2023

Fechas de registro del estudio

Enviado por primera vez

24 de junio de 2021

Primero enviado que cumplió con los criterios de control de calidad

7 de septiembre de 2021

Publicado por primera vez (Actual)

17 de septiembre de 2021

Actualizaciones de registros de estudio

Última actualización publicada (Actual)

29 de septiembre de 2022

Última actualización enviada que cumplió con los criterios de control de calidad

28 de septiembre de 2022

Última verificación

1 de septiembre de 2022

Más información

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .

Suscribir